Peter Attia MD"Anti-Aging" Drugs — NAD, metformin, & rapamycin | The Peter Attia Drive Podcast (Ep 207, AMA 35)
Episode Details
EPISODE INFO
- Released
- May 16, 2022
- Duration
- 29m
- Channel
- Peter Attia MD
- Watch on YouTube
- ▶ Open ↗
EPISODE DESCRIPTION
Become a member to watch this full episode: https://bit.ly/37MLc4J See episode show notes here: https://bit.ly/3Lcz3Ul Sign up to receive Peter's email newsletter: https://bit.ly/4c602k2 In this “Ask Me Anything” (AMA) episode, Peter is joined by special guest, Dr. Matt Kaeberlein. Together they answer many questions around the field of aging with an emphasis on three specific molecules—NAD, metformin, and rapamycin—and their purported geroprotective qualities. They first discuss aging biomarkers and epigenetic clocks before breaking down the advantages and limitations of the most common experimental models being used today to study aging and pharmacological possibilities for extending lifespan. Next they dive deep into NAD and the much-hyped NAD precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They compare data from NAD precursors to studies on metformin and rapamycin, assessing how they stack up against each other and using the comparison as an opportunity to illustrate how to make sense of new experimental data and make smart decisions about how to approach future research. In this sneak peek, we discuss: 00:00 - Logic behind comparing NAD precursors to rapamycin and metformin; 03:49 - Aging biomarkers: current state, usefulness, and future promise; 12:37 - Epigenetic clocks: definition, use case, and limitations; In the full episode, we also discuss:
- Advantages and limitations of studying aging in non-humans and the strengths and weaknesses of different model systems;
- Aging studies: importance of control lifespans and the problems with reproducibility;
- Intro to NAD, potential role in aging, relationship to sirtuins, and more;
- NAD precursors (NR and NMN): current data;
- Human studies with NAD precursors;
- Comparing NAD lifespan data to data from metformin and rapamycin;
- Defining a “clean drug” and a “dirty drug”;
- Reason for the lack of rapamycin studies in humans compared to NAD and metformin;
- Ranking the geroprotective molecules in terms of risk and reward; and
- More.
-------- About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 40 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://bit.ly/3Mg5zGz Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle
SPEAKERS
Peter Attia
hostPhysician and host of The Peter Attia Drive podcast focused on longevity and medicine.
Dr. Matt Kaeberlein
guestGeroscience researcher known for work on aging biology, geroprotectors, and lifespan studies in model organisms.
EPISODE SUMMARY
In this episode of Peter Attia MD, featuring Peter Attia and Dr. Matt Kaeberlein, "Anti-Aging" Drugs — NAD, metformin, & rapamycin | The Peter Attia Drive Podcast (Ep 207, AMA 35) explores why Aging Biomarkers and Epigenetic Clocks Remain Unproven, Say Attia and Kaeberlein The episode is a three-person AMA format built from audience questions about NAD precursors, rapamycin and metformin, with Matt Kaeberlein joining Peter Attia to compare the evidence for each.
RELATED EPISODES
